Press release from Companies: Second cohort in Aptahem’s FIH study performed and approved by the ethics committee

Press release from Companies: Kohort 2 i Aptahems fas 1-studie genomförd och godkänd av etikkommittén

Press release from Companies: BioStock-artikel: Aptahem hoppas nå flera milstolpar under 2023

Press release from Companies: First cohort dosed in Aptahem’s FIH study

Press release from Companies: Kohort 1 genomförd i Aptahems fas 1-studie

Press release from Companies: Newsletter 2022

Press release from Companies: Nyhetsbrev december 2022

Market Notices: Market Notice 224/22 – Last day of trading in Aptahem AB’s BTA

Press release from Companies: Aptahem AB (publ) meddelar sista dag för handel med BTA

Press release from Companies: First subjects dosed in Aptahem’s FIH study

Press release from Companies: Första dosering av friska frivilliga i Aptahems kliniska fas 1-studie

Press release from Companies: Aptahem AB (publ) offentliggör utfall i företrädesemission